Compare Recursion Pharmaceuticals Inc (RXRX) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Zscaler Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $4.41 (market cap $2.14B), while Zscaler Inc trades at $230.62 (market cap $35.35B). The key difference: Zscaler Inc is far larger — about 16.5× Recursion Pharmaceuticals Inc's market cap, and Zscaler Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Zscaler Inc for 41 Days on average.
| RXRX | ZS | |
|---|---|---|
Market Cap | $2.14B | $35.35B |
Volume | 30,789,535 | 3,726,203 |
Sector | Health | Technology |
52-Week High | $6.79 | $336.27 |
52-Week Low | $2.84 | $118.05 |
Typical Hold Time | 22 Days | 41 Days |
Enterprise Value | $1.66B | $33.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Zscaler (ZS) trades at $213.55, up 0.61% with strong technical momentum as the stock approaches resistance near $216. The company demonstrates robust revenue growth, increasing from $1.1B in 2022 to $2.67B in 2025, while narrowing net losses from -$390M to -$41M. Recent earnings beats and 79.6% analyst buy ratings support positive sentiment, though negative profitability metrics and high valuation multiples present challenges.
The outlook remains cautiously optimistic with a $222.83 consensus price target suggesting 4.3% upside potential. Key opportunities include accelerating AI security demand and expanding platform adoption, while risks involve continued profitability challenges, executive transitions, and competitive pressures in the cybersecurity sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
